Clinical Trials Logo

Lung Neoplasm Malignant clinical trials

View clinical trials related to Lung Neoplasm Malignant.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05404022 Completed - Clinical trials for Lung Neoplasm Malignant

Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years

CanBenefitII
Start date: June 20, 2022
Phase: N/A
Study type: Interventional

People with cancer affecting the lungs tend to be older and frailer compared to people with other cancers. As a result, they may have poorer quality of life and are less able to tolerate treatments for their cancer, such as chemotherapy. Research to date show that nutrition and physical activity support helps people with cancer, but not many older people are included in these studies. The investigators want to develop and test a nutrition and activity programme for older people with lung cancer that can be tailored to each patient to help them have the best possible quality of life from the moment they start a new line of cancer treatment. The research team has conducted the development work to find which nutrition and activity programmes are best for this patient group and how best to deliver the programme by looking at prior studies and talking to patients and carers as well as health care providers. The next step is to test the developed programme in a small pilot study, to i) see if it is possible and acceptable (to patients, families, and staff) to deliver and ii) see if it helps patients have and cope with anti-cancer treatments and improve patient quality of life.

NCT ID: NCT04059887 Completed - Clinical trials for Lung Neoplasm Malignant

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

BUDDY
Start date: December 18, 2019
Phase: Phase 4
Study type: Interventional

This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of chemotherapy including at least 1 platinum-based.

NCT ID: NCT03834116 Completed - Clinical trials for Lung Neoplasm Malignant

Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies

Start date: November 23, 2019
Phase: N/A
Study type: Interventional

A small-scale pilot randomized controlled trial conducted by the investigators demonstrated some preliminary evidence that inspiratory muscle training (IMT) could be a promising self-management method for alleviating breathlessness. Hence, the aim of this study is to assess the effectiveness of IMT in patients with thoracic malignancies on dyspnea.

NCT ID: NCT03824977 Completed - Clinical trials for Lung Neoplasm Malignant

Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery

PREOTEST
Start date: November 21, 2018
Phase:
Study type: Observational [Patient Registry]

The objective of this study is to evaluate the performances of the Six-Minute Stepper Test (6MST) and Sit To Stand test (STST) to predict post-operative complications after minimally invasive lung cancer resection.

NCT ID: NCT03352245 Completed - Clinical trials for Lung Neoplasm Malignant

Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer

Start date: November 26, 2018
Phase: N/A
Study type: Interventional

The investigators will evaluate the feasibility of implementing a low-intensity, patient-centered activity regimen (PCAR) that prioritizes education and communication over a 12-week period in advanced stage lung cancer patients. The primary outcomes will include number of patients increasing their overall step count over the study period and adherence to step count recommendations. Secondary outcomes will include quality of life (QoL), dyspnea, and depression scores before and after the intervention as well as a patient feedback questionnaire (to guide further interventions). The goals are to increase overall step count and obtain adherence of >50% of participants. The investigators will also assess whether the physical activity regimen influences markers of inflammation and glucose control and novel markers of cancer.